Spectroscopic characteristics and site I/site II classification of cis and trans benzo[a]pyrene diolepoxide enantiomer-guanosine adducts in oligonucleotides and plynucleotides
Abstract:The highly tumorigenic isomer (+)-7,8-dihydroxy-anti-9, 10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene [(+)-anti-BPDE] and its non-tumorigenic enantiomer (-)-anti-BPDE are known to react predominantly with the exocyclic amino group (N2) of deoxyguanine in DNA and to form adducts of different conformations. The spectroscopic characteristics (UV absorbance, fluorescence and circular dichroism) of stereochemically defined (+)-trans, (-)-trans, (+)-cis and (-)-cis d(5'-CACATGBPDETACAC) adducts in the single-stranded f… Show more
“…Meanwhile, there is no significant difference in the ratio of four adducts between 25 and 37 • C. The yield of cis-(+)-anti-BPDE-N 2 -dG is the lowest (∼2.2-2.5% of total adducts), which is 20 times lower than that of trans-(+)-anti-BPDE-N 2 -dG (∼50% of total adducts). The low yield of the cis-(+)-anti-BPDE-N 2 -dG was consistent with its chemical instability [27]. By the established synthesis method, enzymatic digestion process is no longer required, and carcinogenic anti-BPDE (∼0.1 mg) is 10-100 fold less consumed than reported methods [19,20,23].…”
Section: Synthesis Of Anti-bpde-n 2 -Dgssupporting
“…Meanwhile, there is no significant difference in the ratio of four adducts between 25 and 37 • C. The yield of cis-(+)-anti-BPDE-N 2 -dG is the lowest (∼2.2-2.5% of total adducts), which is 20 times lower than that of trans-(+)-anti-BPDE-N 2 -dG (∼50% of total adducts). The low yield of the cis-(+)-anti-BPDE-N 2 -dG was consistent with its chemical instability [27]. By the established synthesis method, enzymatic digestion process is no longer required, and carcinogenic anti-BPDE (∼0.1 mg) is 10-100 fold less consumed than reported methods [19,20,23].…”
Section: Synthesis Of Anti-bpde-n 2 -Dgssupporting
“…63 The stereo-chemical properties of the modified oligonucleotides were established by enzyme digestion of the modified oligonucleotides and HPLC co-elution of the BPDE-modified base with stereochemically defined trans-anti- [BP]G adduct standards. 64 The stereochemical properties of each mononucleotide adduct were identified by circular dichroism techniques, and by co-elution with the corresponding mononucleotide adduct standards as described earlier for the same B[a]PDE-modified oligonucleotides. 32 earlier.…”
Section: Synthesis Of Site-specifically Modified Oligonucleotidesmentioning
It is well known that CpG dinucleotide steps in DNA, which are highly methylated at the 5-position of cytosine (meC) in human tissues, exhibit a disproportionate number of mutations within certain codons of the p53 gene. There is ample published evidence indicating that the reactivity of guanine with anti-B[a]PDE (a metabolite of the environmental carcinogen benzo[a]pyrene) at CpG mutation hot spots is enhanced by the methylation of the cytosine residue flanking the target guanine residue on the 5′-side. In this work we demonstrate that such a methylation can also dramatically affect the conformational characteristics of an adduct derived
HHS Public Access
“…The oligonucleotides were synthesized using the phosphoramidite method, purified, reacted with BPDE, and the BPDE-oligonucleotide adducts were purified as described earlier [2,3].…”
Section: Methodsmentioning
confidence: 99%
“…We have recently succeeded in synthesizing stereospecific BPDE-oligonucleotide adducts by direct synthesis methods [2,3]. Both (+)-and (-)-BPDE give rise to N2-guanine-ClO BPDE adducts via trans and cis addition of dG relative to the 9,10-oxirane moiety of BPDE [2,4].…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.